CA2964179A1 - Anticorps monoclonaux anti-gpc-1- et leurs utilisations - Google Patents

Anticorps monoclonaux anti-gpc-1- et leurs utilisations Download PDF

Info

Publication number
CA2964179A1
CA2964179A1 CA2964179A CA2964179A CA2964179A1 CA 2964179 A1 CA2964179 A1 CA 2964179A1 CA 2964179 A CA2964179 A CA 2964179A CA 2964179 A CA2964179 A CA 2964179A CA 2964179 A1 CA2964179 A1 CA 2964179A1
Authority
CA
Canada
Prior art keywords
seq
antibodies
binding fragments
antibody population
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2964179A
Other languages
English (en)
Other versions
CA2964179C (fr
Inventor
Douglas Campbell
Irene JUSTINIANO FUENMAYOR
Aline NOCON
Julie SOON
Quach TRUONG
Bradley Walsh
Sandra Wissmueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glyp Holdings Pty Ltd
Original Assignee
Minomic International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic International Ltd filed Critical Minomic International Ltd
Publication of CA2964179A1 publication Critical patent/CA2964179A1/fr
Application granted granted Critical
Publication of CA2964179C publication Critical patent/CA2964179C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente demande concerne une invention basée sur la découverte que l'anticorps BLCA-38 est en réalité une population d'anticorps comprenant deux anticorps monoclonaux distincts. Les revendications définissent une population d'anticorps isolée comprenant des premiers anticorps et/ou des fragments de liaison d'antigène de ceux-ci définis par des régions spécifiques variables à chaîne lourde et à chaîne légère, et où la population d'anticorps ne contient pas de seconds anticorps définis par des régions spécifiques variables à chaîne légère. Les revendications définissent également des cellules d'hybridome, des cultures capables de produire de telles populations d'anticorps, des compositions comprenant de telles populations d'anticorps, des molécules d'acides nucléiques codant pour de tels anticorps, des vecteurs, des cellules hôtes de ceux-ci, et des procédés pour la production des populations d'anticorps de l'invention.
CA2964179A 2014-10-23 2014-10-23 Anticorps monoclonaux anti-gpc-1- et leurs utilisations Active CA2964179C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/AU2014/000999 WO2016061608A1 (fr) 2014-10-23 2014-10-23 Anticorps monoclonaux anti-gpc-l- et leurs utilisations

Publications (2)

Publication Number Publication Date
CA2964179A1 true CA2964179A1 (fr) 2016-04-28
CA2964179C CA2964179C (fr) 2023-04-11

Family

ID=55759935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964179A Active CA2964179C (fr) 2014-10-23 2014-10-23 Anticorps monoclonaux anti-gpc-1- et leurs utilisations

Country Status (11)

Country Link
US (1) US10577418B2 (fr)
EP (1) EP3209686B1 (fr)
JP (1) JP6749901B2 (fr)
KR (1) KR102249981B1 (fr)
CN (1) CN107108734B (fr)
AU (1) AU2014409558B2 (fr)
CA (1) CA2964179C (fr)
DK (1) DK3209686T3 (fr)
ES (1) ES2778100T3 (fr)
SG (1) SG11201703006QA (fr)
WO (1) WO2016061608A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708624YA (en) * 2015-04-20 2017-11-29 Minomic Int Ltd Therapeutic antibodies and uses thereof
JPWO2018199318A1 (ja) * 2017-04-28 2020-03-12 国立大学法人高知大学 抗ｇｐｃ−１抗体
US20220098323A1 (en) * 2019-01-22 2022-03-31 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
JP2020007315A (ja) * 2019-08-02 2020-01-16 ミノミック インターナショナル リミティド モノクローナル抗ｇｐｃ−１抗体およびその使用
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504466A (ja) * 1989-05-24 1993-07-15 ザ　セントラル　シドニー　エリア　ヘルス　サービス 膀胱癌からの悪性細胞を認識するモノクローナル抗体
US5622836A (en) * 1989-05-24 1997-04-22 The University Of Sydney Monoclonal antibodies which recognize malignant cells from bladder carcinomas
WO1990014433A1 (fr) 1989-05-24 1990-11-29 The University Of Sydney Anticorps monoclonaux reconnaissant les cellules malignes provenant de carcinomes cystiques
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
CN101070345B (zh) * 2006-05-12 2010-09-29 中国科学院上海生命科学研究院 抗前列腺特异抗原psa单克隆抗体及应用
KR102366820B1 (ko) 2014-01-17 2022-02-22 미노믹 인터내셔널 리미티드 진단을 위한 세포 표면 전립선암 항원
WO2016112423A1 (fr) 2015-01-16 2016-07-21 Minomic International Ltd. Épitopes de la glypicane et leurs utilisations
SG11201708624YA (en) 2015-04-20 2017-11-29 Minomic Int Ltd Therapeutic antibodies and uses thereof

Also Published As

Publication number Publication date
JP6749901B2 (ja) 2020-09-02
AU2014409558A8 (en) 2019-08-08
CN107108734A (zh) 2017-08-29
KR102249981B1 (ko) 2021-05-11
WO2016061608A1 (fr) 2016-04-28
EP3209686A1 (fr) 2017-08-30
EP3209686A4 (fr) 2018-03-07
AU2014409558B2 (en) 2021-08-12
ES2778100T3 (es) 2020-08-07
WO2016061608A8 (fr) 2017-06-29
US10577418B2 (en) 2020-03-03
EP3209686B1 (fr) 2019-12-25
CN107108734B (zh) 2021-09-14
CA2964179C (fr) 2023-04-11
JP2017531442A (ja) 2017-10-26
DK3209686T3 (da) 2020-03-16
AU2014409558A1 (en) 2017-05-04
KR20170085051A (ko) 2017-07-21
SG11201703006QA (en) 2017-05-30
US20180072803A1 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
CN111454357B (zh) 一种含有抗体的肿瘤治疗剂的开发和应用
KR102022734B1 (ko) 신규 조절제 및 용법
RU2430112C2 (ru) Композиции и способы диагностики и лечения опухоли
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
WO2019042119A1 (fr) Anticorps dirigé contre cd47 humain et son utilisation
AU2017316473A1 (en) Anti-Tim-3 antibodies
JP2020500003A5 (fr)
JP2013502913A5 (fr)
CA2964179A1 (fr) Anticorps monoclonaux anti-gpc-1- et leurs utilisations
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2022523543A (ja) 二機能性融合タンパク質及びその医薬的使用
WO2020114479A1 (fr) Molécule de protéine multispécifique
JP2020521504A (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
KR102486507B1 (ko) 플렉틴-1 결합 항체 및 그의 용도
WO2021098822A1 (fr) Anticorps bispécifiques
JP2020508658A (ja) Ｔｉｍ−３抗体、その抗原結合断片、及びそれらの医学的使用
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
WO2020114478A1 (fr) Anticorps cd3 et son utilisation pharmaceutique
JP2017521054A5 (fr)
WO2022267936A1 (fr) Anticorps spécifiquement lié à ceacam5 glycosylé
WO2013157102A1 (fr) Anticorps humain spécifique à la mucine 5ac et son utilisation
WO2022095934A1 (fr) Anticorps anti-siglec-15 et son utilisation dans la préparation d'un médicament
JP2023109923A (ja) グロボｈに対するヒト化抗体および癌治療におけるその使用
CN113597432B (zh) 抗EpCAM抗体及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191010

EEER Examination request

Effective date: 20191010

EEER Examination request

Effective date: 20191010

EEER Examination request

Effective date: 20191010

EEER Examination request

Effective date: 20191010

EEER Examination request

Effective date: 20191010